Sales – occupational activity
Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns
Sarepta Therapeutics; Elevidys; Q2 2025; gene therapy; sales performance; FDA; safety issues; shipment pause
Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance
Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition
Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul
Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development
CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling
Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion
Bavarian Nordic Sells FDA Priority Review Voucher for $160M Amid Rising Industry Prices and Program Scrutiny
Bavarian Nordic; Priority Review Voucher; FDA; voucher sale; $160 million; chikungunya vaccine; VIMKUNYA; NIH; antitrust review; biotech finance
23andMe to Restart Auction After Former CEO Anne Wojcicki Outbids Regeneron
23andMe; auction; Anne Wojcicki; Regeneron; TTAM Research Institute; bankruptcy; asset sale; genetics
iTeos to Shut Down Operations After TIGIT Therapy Setback
iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program
Pivotal readouts on deck as Takeda sees stagnant sales this year
Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY
Biogen says Leqembi sales are improving slowly following lackluster launch
Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)
Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments
False Claims Act, Medicare fraud, average sales price inflation, credit card fees, price concessions, DOJ lawsuit